sotorasib
amgen
['sclc', 'nsclc', 'sotorasib']
scarlett study: ph2 study of kras g12c inhibitor sotorasib in combination with pem/carbo in nsclc 89% orr
72% gr3+ toxicity several studies ongoing combining kras inhibitors though will the toxicities of combination preclude progress?
#asco2023 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18